Revive Therapeutics Sees FDA Recommend Phase 3 For COVID-19 Related Study Of Bucillamine

Revive Therapeutics (CSE: RVV) announced major news this morning related to its ongoing study of Bucillamine, with the US Food and Drug Administration recommending that the company proceed straight to a phase three confirmatory clinical trial to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection.

The news is significant as it means that Revive will be able to skip over the phase two clinical study portion of the FDA’s process, enabling the product to get to market sooner than expected if proven effective against the infectious disease. The push to phase three on the study of Bucillamine will enable the company to expeditiously evaluate the safety and efficacy of the drug.

In addition to the recommendation provided, the FDA also provided guidance on the study design and outcome measures for the phase 3 study. More importantly, the FDA identified that as a result of Revive’s previous work with the drug on the treatment of gout, the data provided from that study could be used to skip over phase 1 and 2 of the clinical study process. The firms contract research team, Pharm-Olam, is actively working towards assembling the final investigation new drug (IND) for submission to the FDA within the next 60 days, after which the firm will begin its phase 3 trials.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Revive Therapeutics last traded at $0.18 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Majestic Hits 4.24 g/t Gold Over 48.8 Metres at Saval as Jerritt Canyon Restart Advances

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Related News

Initial Jobless Claims in the US Continue to Surpass Economists’ Forecasts

Although the US economy was beginning to show signs of a rebound, the positive sentiment...

Friday, June 26, 2020, 03:33:00 PM

New Coronavirus Cases Surge By 30% In One Week As US States Lift Restrictions

As the US is well underway in lifting restrictions and reopening its economy, the number...

Wednesday, June 24, 2020, 07:15:00 PM

Apple Plans to Move 20% of Production from China to India in Response to Coronavirus Chaos

As the coronavirus pandemic continues to wreak havoc around the world, several large companies are...

Wednesday, May 13, 2020, 12:02:00 PM

US Consumer Sentiment Slumps to Decade Low Amid Delta Variant, Inflation Concerns

Americans’ optimism surrounding the recovery of the US economy slumped to the lowest in a...

Sunday, August 15, 2021, 03:05:00 PM

Could There Be a Global Food Shortage? You Betcha’

The COVID-19 pandemic has led to the UN warning the public about the possibility of...

Tuesday, March 31, 2020, 08:33:33 PM